Petros Pharmaceuticals, Inc.
PTPI · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | -$0 | -$0 | $0 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | -100% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | 63.5% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | -1,163.3% |
| Net Income | -$0 | $0 | -$0 | -$0 |
| % Margin | – | – | – | -1,278.4% |
| EPS Diluted | -0.022 | -1.29 | -9.37 | -0.13 |
| % Growth | 98.3% | 86.2% | -7,107.7% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | $0 |
| Capital Expenditures | $0 | $0 | $0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | $0 |